Reacción a "EMA revises earlier decision and decides to approve lecanemab for Alzheimer's disease"

This is the news we were waiting for with a certain amount of caution, because the EMA is a very conservative body that evaluates the risk situation of patients very carefully, which was one of the key points here for accepting treatment with Leqembi.

This is the best news we have had this year. Europe needed this news. Europe needed to know that we had the possibility of treating patients, we needed to know that all research in this field would continue and that we understood, as was already done in the document and the paper sent by the European Alzheimer's Disease Consortium, that what had to be very well defined were the restrictions, taking into account the validity and experience of the prescribing centres that have had - even if they had previous experience in clinical trials of monoclonal antibody treatment. This acceptance by the EMA balances the situation so that our patients in Europe and Spain have the same opportunities as others.